Safety, Tolerability and Pharmacokinetics of Single Rising Doses of 0.5 mug, 2.5 mug, 5 mug, 10 mug, 15 mug, 20 mug, 25 mug and 30 mug BI 1744 CL (Calculated as Free Base) Given as Intravenous Infusion Over 30 Minutes to Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.

Trial Profile

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of 0.5 mug, 2.5 mug, 5 mug, 10 mug, 15 mug, 20 mug, 25 mug and 30 mug BI 1744 CL (Calculated as Free Base) Given as Intravenous Infusion Over 30 Minutes to Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Olodaterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top